secwatch.observer — SEC 8-K summary
======================================

Issuer:     Raphael Pharmaceutical Inc. (RAPH)
CIK:        0001415397
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001213900-24-039106
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Raphael Pharma launches US proof-of-concept CBG trial for rheumatoid arthritis
------------------------------------------------------------------------------

- Proof-of-concept clinical trial begun in US for Cannabigerol (CBG) in active Rheumatoid Arthritis patients.
- Engaged MindMate/Citruslabs to oversee trial; estimated timeline 6 months from first participant recruitment.
- Trial leverages pre-clinical experiments conducted at Rambam Health Care Campus, Israel.
- No financial guidance or material financial impact disclosed in filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1415397/000121390024039106/0001213900-24-039106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1415397/000121390024039106/ea0205172-8k_raphael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-039106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer